Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Arcutis Biotherapeutics (ARQT) over the last 7 years, with Dec 2024 value amounting to $66.2 million.

  • Arcutis Biotherapeutics' Cash from Financing Activities rose 274.62% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.2 million, marking a year-over-year decrease of 135.82%. This contributed to the annual value of $66.2 million for FY2024, which is 34.66% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Cash from Financing Activities stood at $66.2 million for FY2024, which was down 34.66% from $101.3 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Cash from Financing Activities registered a high of $301.8 million during FY2022, and its lowest value of $66.2 million during FY2024.
  • For the 3-year period, Arcutis Biotherapeutics' Cash from Financing Activities averaged around $156.4 million, with its median value being $101.3 million (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 220.23% in 2020, then crashed by 66.43% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Cash from Financing Activities (Yearly) stood at $298.1 million in 2020, then dropped by 5.43% to $281.9 million in 2021, then grew by 7.04% to $301.8 million in 2022, then slumped by 66.43% to $101.3 million in 2023, then slumped by 34.66% to $66.2 million in 2024.